New combo targets tough lung cancer in early trial

NCT ID NCT04780568

Ongoing Disease control Sponsor: Ohio State University Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This early-phase trial is testing two drugs, osimertinib and tegavivint, as a first treatment for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC that has spread). The goal is to find the best dose and see if the combination is safe and shrinks tumors. About 24 adults with this cancer will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Osimertinib and Tegavivint
What this could lead to: If it works, this could point toward a more effective first-line treatment for EGFR-mutant lung cancer that has spread.
What could go wrong: This is a very early phase 1 trial with only 24 people, so it may not show clear benefit. Side effects from the drug combination are unknown and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC LUNG NON-SMALL CELL CARCINOMA STAGE IV LUNG CANCER AJCC V8 STAGE IVA LUNG CANCER AJCC V8 STAGE IVB LUNG CANCER AJCC V8

Contacts and locations

Locations

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.